中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 4
Apr.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(4): 684-689

Value of serum Aldo-keto reductase family 1 member B10 （AKR1B10） in diagnosis of hepatocellular carcinoma

DOI: 10.12449/JCH250413
  • 1.

    Department of Clinical Laboratory，South Branch of The Affiliated Hospital of Chengde Medical University，Chengde，Hebei 067000，China

  • 2.

    First Department of Integrated Traditional Chinese and Western Medicine，Beijing Ditan Hospital，Capital Medical University，Beijing 100015，China

Research funding:

S & T Program of Chengde (202109A064);

The Cultivating Programme Plan for Excellent Talent of Hebei in 2024 (ZF2024237)

  • Received Date: 2024-09-06
  • Accepted Date: 2024-10-10
  • Published Date: 2025-04-25
    Abstract
  •   Objective  To investigate the expression of serum Aldo-keto reductase family 1 member B10 （AKR1B10） in patients with hepatocellular carcinoma （HCC） in northern China， and to provide a new and valuable biomarker for the clinical diagnosis of HCC.  Methods  This study was conducted among 102 patients with HCC， 119 patients with benign liver disease， and 132 patients with other malignant tumors who attended The Affiliated Hospital of Chengde Medical University and 148 healthy individuals who underwent physical examination from May 2020 to May 2024. ELISA and chemiluminescence were used to measure the serum levels of AKR1B10 and alpha-fetoprotein （AFP）. The Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups， and the Kruskal-Wallis H test was used for comparison between three groups and further comparison between two groups； the chi-square test was used for comparison of categorical data between groups. The area under the ROC curve （AUC） was used to assess diagnostic efficiency.  Results  The expression level of AKR1B10 was 3 053.79 （1 475.67‍ ‍—‍ ‍4 605.86） pg/mL in the HCC group， 1 324.42 （659.68‍ ‍—‍ ‍2 023.88） pg/mL in the benign liver disease group， 660.68 （377.56‍ ‍—‍ ‍2 087.77） pg/mL in the other malignant tumor group， and 318.30 （82.73‍ ‍—‍ ‍478.82） pg/mL in the healthy group， with a significant difference between the four groups （H=240.86， P<0.001）， and further comparison between two groups showed that the HCC group had a significantly higher level than the other three groups （all P<0.001）. The ROC curve analysis of the HCC group and the other three groups showed that serum AKR1B10 had an optimal cut-off value of 1 584.97 pg/mL in the diagnosis of HCC， with an AUC of 0.86 （95% confidence interval ［CI］： 0.82‍ ‍—‍ ‍0.90）， a sensitivity of 74.3%， and a specificity of 85.2%. Compared with each indicator alone， a combination of AKR1B10 and AFP could improve the sensitivity （81.8%） and specificity （91.4%） of HCC diagnosis. AKR1B10 had an AUC of 0.84 （95%CI： 0.78‍ ‍—‍ ‍0.90） in the diagnosis of patients with early- or middle-stage HCC， with a sensitivity of 76.2% and a specificity of 81.2%. AKR1B10 had an AUC of 0.85 （95%CI： 0.77‍ ‍—‍ ‍0.92） in the diagnosis of patients with AFP-negative HCC， with a sensitivity of 81.6% and a specificity of 79.9%.  Conclusion  AKR1B10 is a promising serological marker for the diagnosis of HCC， and a combination of AKR1B10 and AFP can improve the detection rate of HCC patients in northern China， especially those with early- or middle-stage HCC and AFP-negative HCC.

     

    • FullText(HTML)
  • loading
    • References(24)
  • [1]
    SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71( 3): 209- 249. DOI: 10.3322/caac.21660.
    [2]
    LIU YX, ZHENG ZB. Understanding the global cancer statistics 2022: Growing cancer burden[J]. Sci China Life Sci, 2024, 67( 10): 2274- 2276. DOI: 10.1007/s11427-024-2657-y.
    [3]
    RUMGAY H, ARNOLD M, FERLAY J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040[J]. J Hepatol, 2022, 77( 6): 1598- 1606. DOI: 10.1016/j.jhep.2022.08.021.
    [4]
    National Health Commission of the People’s Republic of China. Standard for diagnosis and treatment of primary liver cancer(2024 edition)[J]. J Clin Hepatol, 2024, 40( 5): 893- 918. DOI: 10.12449/JCH240508.

    中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2024年版)[J]. 临床肝胆病杂志, 2024, 40( 5): 893- 918. DOI: 10.12449/JCH240508.
    [5]
    LU J, ZHANG XP, ZHONG BY, et al. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: Comparing east and west[J]. Lancet Gastroenterol Hepatol, 2019, 4( 9): 721- 730. DOI: 10.1016/S2468-1253(19)30178-5.
    [6]
    DING CM, HOU JF, TAO GW, et al. Early diagnosis and screening of hepatocellular carcinoma[J/OL]. Chin J Hepat Surg(Electronic Edition), 2023, 12( 1): 22- 28. DOI: 10.3877/cma.j.issn.2095-3232.2023.01.005.

    丁成明, 侯嘉丰, 陶光伟, 等. 肝细胞癌早期诊断和筛查[J/OL]. 中华肝脏外科手术学电子杂志, 2023, 12( 1): 22- 28. DOI: 10.3877/cma.j.issn.2095-3232.2023.01.005.
    [7]
    WANG XP, WANG QX. Alpha-fetoprotein and hepatocellular carcinoma immunity[J]. Can J Gastroenterol Hepatol, 2018, 2018: 9049252. DOI: 10.1155/2018/9049252.
    [8]
    LU QQ, LI J, CAO H, et al. Comparison of diagnostic accuracy of Midkine and AFP for detecting hepatocellular carcinoma: A systematic review and meta-analysis[J]. Biosci Rep, 2020, 40( 3): BSR20192424. DOI: 10.1042/BSR20192424.
    [9]
    YU XP, YANG RY, HE ZM, et al. Establishment and validation of nomogram of cancer specific survival of patients with hepatocellular carcinoma with negative alpha fetoprotein based on SEER Database[J]. J Jilin Univ(Med Edit), 2024, 50( 1): 188- 197. DOI: 10.13481/j.1671-587X.20240123.

    余孝鹏, 杨仁义, 贺佐梅, 等. 基于SEER数据库建立和验证甲胎蛋白阴性肝细胞癌患者癌症特异生存期的列线图[J]. 吉林大学学报(医学版), 2024, 50( 1): 188- 197. DOI: 10.13481/j.1671-587X.20240123.
    [10]
    LIU YZ, ZHANG J, LIU H, et al. Compensatory upregulation of aldo-keto reductase 1B10 to protect hepatocytes against oxidative stress during hepatocarcinogenesis[J]. Am J Cancer Res, 2019, 9( 12): 2730- 2748.
    [11]
    SINGAL AG, LLOVET JM, YARCHOAN M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma[J]. Hepatology, 2023, 78( 6): 1922- 1965. DOI: 10.1097/hep.0000000000000466.
    [12]
    FORNER A, REIG M, BRUIX J. Hepatocellular carcinoma[J]. Lancet, 2018, 391( 10127): 1301- 1314. DOI: 10.1016/s0140-6736(18)30010-2.
    [13]
    MORIGUCHI M, KATAOKA S, ITOH Y. Evolution of systemic treatment for hepatocellular carcinoma: Changing treatment strategies and concepts[J]. Cancers(Basel), 2024, 16( 13): 2387. DOI: 10.3390/cancers16132387.
    [14]
    YUE YX, NING SK, LIU JB, et al. Comparative analysis of the efficacy of interventional therapy and interventional therapy combined with targeted drugs for advanced primary liver cancer[J]. Chin J Cancer Prev Treat, 2021, 28( 10): 788- 791. DOI: 10.16073/j.cnki.cjcpt.2021.10.13.

    岳衍晓, 宁尚昆, 刘吉兵, 等. 晚期原发性肝癌介入治疗与联合靶向药物治疗效果对比分析[J]. 中华肿瘤防治杂志, 2021, 28( 10): 788- 791. DOI: 10.16073/j.cnki.cjcpt.2021.10.13.
    [15]
    FU YL, SHI WX, HUANG S, et al. Comparison of prognostic evaluation and therapeutic guidance value of three clinical staging systems for hepatocellular carcinoma[J]. J Guangxi Med Univ, 2018, 35( 12): 1706- 1709. DOI: 10.16190/j.cnki.45-1211/r.2018.12.025.

    付艳龙, 石文新, 黄山, 等. 肝细胞癌3种临床分期系统预后评估和治疗指导价值的比较[J]. 广西医科大学学报, 2018, 35( 12): 1706- 1709. DOI: 10.16190/j.cnki.45-1211/r.2018.12.025.
    [16]
    YE X, LI CY, ZU XY, et al. A large-scale multicenter study validates aldo-keto reductase family 1 member B10 as a prevalent serum marker for detection of hepatocellular carcinoma[J]. Hepatology, 2019, 69( 6): 2489- 2501. DOI: 10.1002/hep.30519.
    [17]
    HUNG JJ, YEH YC, HSU WH. Prognostic significance of AKR1B10 in patients with resected lung adenocarcinoma[J]. Thorac Cancer, 2018, 9( 11): 1492- 1499. DOI: 10.1111/1759-7714.12863.
    [18]
    ENDO S, MATSUNAGA T, NISHINAKA T. The role of AKR1B10 in physiology and pathophysiology[J]. Metabolites, 2021, 11( 6): 332. DOI: 10.3390/metabo11060332.
    [19]
    SHI J, CHEN LX, CHEN Y, et al. Aldo-Keto Reductase Family 1 Member B10(AKR1B10) overexpression in tumors predicts worse overall survival in hepatocellular carcinoma[J]. J Cancer, 2019, 10( 20): 4892- 4901. DOI: 10.7150/jca.32768.
    [20]
    QU JY, LI J, ZHANG YM, et al. AKR1B10 promotes breast cancer cell proliferation and migration via the PI3K/AKT/NF-‍κB signaling pathway[J]. Cell Biosci, 2021, 11( 1): 163. DOI: 10.1186/s13578-021-00677-3.
    [21]
    TREVISANI F, GARUTI F, NERI A. Alpha-fetoprotein for diagnosis, prognosis, and transplant selection[J]. Semin Liver Dis, 2019, 39( 2): 163- 177. DOI: 10.1055/s-0039-1677768.
    [22]
    EDOO MIA, CHUTTURGHOON VK, WUSU-ANSAH GK, et al. Serum biomarkers AFP, CEA and CA19-9 combined detection for early diagnosis of hepatocellular carcinoma[J]. Iran J Public Health, 2019, 48( 2): 314- 322.
    [23]
    WANG Y, XU WL, CHAI XZ. Application of combined serum AFP and AKR1B10 in diagnosis of hepatocellular carcinoma[J]. Chin J Integr Tradit West Med Liver Dis, 2020, 30( 6): 541- 543. DOI: 10.3969/j.issn.1005-0264.2020.06.002.

    王月, 许炜璐, 柴晓哲. 血清AKR1B10和甲胎蛋白联合检测对肝细胞癌诊断的意义[J]. 中西医结合肝病杂志, 2020, 30( 6): 541- 543. DOI: 10.3969/j.issn.1005-0264.2020.06.002.
    [24]
    ZHU RP, XIAO J, LUO DT, et al. Serum AKR1B10 predicts the risk of hepatocellular carcinoma—A retrospective single-center study[J]. Gastroenterol Hepatol, 2019, 42( 10): 614- 621. DOI: 10.1016/j.gastrohep.2019.06.007.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (566) PDF downloads(39) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return